D3 Bio Advances KRAS Franchise With Multiple Clinical Readouts Slated for AACR 2026

New updates have been reported about D3 Bio.

D3 Bio will use the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego to showcase breadth and early validation of its KRAS‑focused oncology pipeline, with five accepted abstracts, including two high‑visibility oral presentations. The company will present Phase 1/2 data on its lead asset Elisrasib (D3S‑001), a next‑generation GDP‑bound KRAS G12C inhibitor, in advanced non‑small cell lung cancer previously treated with or without a KRAS G12C inhibitor, and in metastatic colorectal and pancreatic ductal adenocarcinoma as monotherapy and in combination with cetuximab.

Three additional posters will detail first‑in‑human data for D3S‑002, a selective ERK1/2 inhibitor designed for combination use to overcome resistance in MAPK‑mutant tumors, and translational pharmacokinetic and mechanistic data for D3S‑003, an orally available dual‑state KRAS G12D inhibitor targeting both GDP‑ and GTP‑bound forms. Management positions these data as reinforcing D3 Bio’s strategy to build a multi‑allele KRAS franchise with global rights retained, aimed at large unmet needs in KRAS‑driven lung, colorectal, and pancreatic cancers. The visibility of plenary and mini‑symposium slots at AACR enhances the company’s scientific profile, could support future partnering or financing discussions, and provides key read‑through on clinical risk, differentiation, and potential combination strategies across its pipeline.